Content
@
0 reply
0 recast
0 reaction
Molecule
@molecule
Why has the UK has just decided that they will not cover the cost of lecanemab, one of the few Alzheimer's medications on the market? ➡️ The drug only moderately slows down the disease ➡️ There are risks of serious, even deadly, side-effects ➡️ Treatment costs over $20k a year It's clear that better solutions are needed. Researchers like Dr Dimitri Scherbakov & Dr Rashid Akbergenov are trying to do just that. There are 4 days left to support their work via Catalyst, the #DeSci funding machine. Follow the link in our bio to learn more! 🖇️
0 reply
0 recast
0 reaction
